DESTINY-BREAST05
Start here
China's NMPA approved on September 29, 2026 Enhertu (trastuzumab deruxtecan), jointly developed and commercialized by AstraZeneca and Daiichi Sankyo, as adjuvant treatment for adults with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane plus trastuzumab-based therapy. The approval rests on the DESTINY-Breast05 phase III trial, presented at ESMO 2025 and published in the New England Journal of Medicine. It is Enhertu's ninth approved indication in China, six of them in breast cancer.
Excerpted from mp.weixin.qq.com
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comNMPA Approves Enhertu for Adjuvant Treatment of HER2-Positive Early Breast Cancer
China's NMPA approved on September 29, 2026 Enhertu (trastuzumab deruxtecan), jointly developed and commercialized by AstraZeneca and Daiichi Sankyo, as adjuvant treatment for adults with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane plus trastuzumab-based therapy. The approval rests on the DESTINY-Breast05 phase III trial, presented at ESMO 2025 and published in the New England Journal of Medicine. It is Enhertu's ninth approved indication in China, six of them in breast cancer.
Heat trend for this story
Heat now 22·Peak in the comparable set 42 (Oct 24 00:00)·Change over 24h in the comparable set -25%·Participants now 6
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.